CD34+ Hematopoietic Stem Cell-Derived iPSC Line
Our ethically sourced CD34+ induced pluripotent stem cells (iPSCs) are derived from healthy cord blood-derived hematopoietic stem cells (HSCs) and reprogrammed using our patented non-integrating episomal DNA technology. This method employs a proprietary mix of transcription factors and small molecule chemistry while excluding oncogenic factors such as L-Myc, C-Myc, and Lin28, ensuring enhanced genomic stability and safety. These iPSCs provide a highly reliable platform for hematopoietic research, disease modeling, drug discovery, and cell therapy applications.
Our CD34+ iPSC cell line exhibits a clean genetic profile, maintaining genomic integrity without accumulating deletions, insertions, or chromosomal translocations after reprogramming. Compared to iPSCs derived from other sources, CD34+ iPSCs demonstrate higher proliferative capacity, improved engraftment potential, and robust pluripotency, making them ideal for blood and immune cell differentiation. We recommend culturing these cells in Human iPSC Growth Media (CET-MR1001-K).
Key Features & Quality Control:
- Pluripotency Validation: Characterized by colony morphology, positive alkaline phosphatase staining, and expression of key pluripotency markers such as SSEA-4.
- High Proliferation Rate: Cells exhibit a 20-hour doubling time, ensuring rapid expansion for downstream applications.
- Genomic Stability: Non-integrating reprogramming prevents unwanted genetic modifications, reducing the risk of tumorigenicity.
- Pathogen-Free: Mycoplasma testing confirms cells are free from contaminants.
- High Viability & Secure Shipping: Each vial contains ~500,000 viable cells, shipped on dry ice or liquid nitrogen for maximum stability.
Applications of iPSCs:
- Hematopoietic Differentiation: Generate blood and immune cell lineages, including erythrocytes, T cells, B cells, and NK cells.
- Disease Modeling: Study genetic disorders such as leukemia, sickle cell disease, and immunodeficiencies.
- Drug Discovery & Toxicology: Screen compounds for hematopoietic disorders and assess immune-modulating drugs.
- Cell Therapy Research: Investigate the therapeutic potential of CD34+ iPSC-derived cells for bone marrow transplantation and regenerative medicine.
With superior pluripotency, genomic stability, and differentiation potential, our CD34+ hematopoietic stem cell-derived iPSC line is a powerful tool for researchers in stem cell biology, immunology, and translational medicine. Order today and advance your research with high-quality iPSC technology.